Structural imaging remains an essential component of diagnosis, staging and response
assessment in patients with cancer; however, as clinicians increasingly seek to …

Context Prostate-specific membrane antigen (PSMA) targeting positron emission
tomography (PET) is emerging to become a reference imaging tool for the staging and …

The authors define molecular imaging, according to the Society of Nuclear Medicine and
Molecular Imaging, as the visualization, characterization, and measurement of biological …

Background Multiparametric magnetic resonance imaging (MRI) is validated for the
detection of clinically significant prostate cancer (csPCa), although patients with …

Importance The presence of pelvic nodal metastases at radical prostatectomy is associated
with biochemical recurrence after prostatectomy. Objective To assess the accuracy of …

Background Conventional imaging using CT and bone scan has insufficient sensitivity when
staging men with high-risk localised prostate cancer. We aimed to investigate whether novel …

Purpose: Current FDA-approved imaging modalities are inadequate for localizing prostate
cancer biochemical recurrence (BCR). 18F-DCFPyL is a highly selective, small-molecule …

Rationale The development of consensus guidelines for interpretation of Prostate-Specific
Membrane Antigen (PSMA)-Positron Emission Tomography (PET) is needed to provide …

Background Innovations in imaging and molecular characterisation and the evolution of new
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …

Here we aim to provide updated guidance and standards for the indication, acquisition, and
interpretation of PSMA PET/CT for prostate cancer imaging. Procedures and characteristics …